Literature DB >> 2453196

Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles.

H D Showalter1, D W Fry, W R Leopold, J W Lown, J A Plambeck, K Reszka.   

Abstract

Chromophore modification of the anthracenediones related to mitoxantrone in an attempt to provide agents with diminished or no cardiotoxicity has resulted in a novel class of DNA binders, the anthrapyrazoles. Selected biochemistry, electrochemistry and tumour biology were carried out for a series of compounds possessing the same upper and lower side chains but with varying A-ring hydroxylation patterns. The anthrapyrazoles bind strongly to DNA, are selective and potent inhibitors of DNA synthesis and cause the formation of single-strand breaks in DNA. They also induced far less (20-200-fold) superoxide dismutase-sensitive oxygen consumption than doxorubicin in the rat liver microsomal system, a property that may be indicative of reduced cardiotoxicity. This result is in accord with their polarographic properties in which the anthrapyrazoles show a much greater resistance to reduction (E'1/2 = -0.983- -1.085 V) relative to daunorubicin (E'1/2 = -0.625 V) and mitoxantrone (E'1/2 = -0.775 V). The anthrapyrazoles demonstrate high levels of activity against a broad range of murine tumours in vivo including the P388 leukaemia and mammary adenocarcinoma 16c lines detailed in this study.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2453196

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  5 in total

1.  The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Authors:  M A Graham; D R Newell; B J Foster; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology.

Authors:  S G Allan; J Cummings; S Evans; M Nicolson; M E Stewart; J Cassidy; M Soukop; S B Kaye; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole.

Authors:  K Bélanger; J Jolivet; J Maroun; D Stewart; A Grillo-Lopez; L Whitfield; N Wainman; E Eisenhauer
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

4.  Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

Authors:  G R Fisher; L H Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Chemotherapy of mammary carcinomas arising in ras transgenic mice.

Authors:  D L Dexter; M Diamond; J Creveling; S F Chen
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.